Vor Ort
Merkzettel Warenkorb
  • Produktbild: Drugs Affecting Lipid Metabolism
  • Produktbild: Drugs Affecting Lipid Metabolism
Band 10

Drugs Affecting Lipid Metabolism

Aus der Reihe Proceedings in Life Sciences

51,99 €

inkl. gesetzl. MwSt., Versandkostenfrei

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.11.2011

Herausgeber

Rodolfo Paoletti + weitere

Verlag

Springer Berlin

Seitenzahl

451

Maße (L/B/H)

24,2/17/2,6 cm

Gewicht

801 g

Auflage

Softcover reprint of the original 1st ed. 1987

Sprache

Englisch

ISBN

978-3-642-71704-8

Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

17.11.2011

Herausgeber

Verlag

Springer Berlin

Seitenzahl

451

Maße (L/B/H)

24,2/17/2,6 cm

Gewicht

801 g

Auflage

Softcover reprint of the original 1st ed. 1987

Sprache

Englisch

ISBN

978-3-642-71704-8

Herstelleradresse

Springer-Verlag KG
Sachsenplatz 4-6
1201 Wien
AT

Email: GPSR Kontakt

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)
  • Produktbild: Drugs Affecting Lipid Metabolism
  • Produktbild: Drugs Affecting Lipid Metabolism
  • Relationship of Cholesterol to DNA Synthesis in Normal and Cancerous Cells.- Turnover of HMG-CoA Reductase is Influenced by Phosphorylation.- Regulation of ACAT.- Dietary and Pharmacological Control of Cholesterol, 7?-Hydroxylase.- Recent Advances in Metabolic Pathways of Bile Acid Synthesis.- Bile Acid Sequestrants: Do They Have a Future?.- Transport of Cholesterol and Cholesterol Esters by HDL.- Role of HDL in the Metabolism of the Plasma Lipoproteins.- The Structure of ApoB-100: Structure-Function Studies.- A Genetic Marker in the Apolipoprotein AI/CIII Gene Complex Associated with Hypercholesterolaemia.- Cellular and Molecular Biology of Apolipoproteins: Receptor-Mediated Regulation of Cholesterol Metabolism.- APOA-I and APOA-II Metabolism and Coronary Artery Disease.- Hypocholesterolemic Drugs and Lipoprotein Metabolism.- Hypotriglyceridemic Drugs and Lipoprotein Catabolism.- Lipolysis and Lipoprotein Metabolism.- Regulation of Lipoprotein Lipase Activity: Its Role in Lipid-Lowering Therapies.- Lipolysis and Antilipolytic Drugs at Different Ages.- Fatty Acid-Binding Proteins of Various Tissues.- Interaction of Lipid-Lowering Drugs with Fatty Acid-Binding Proteins.- Animal Models for Hyperlipidemia-Induced Atherosclerosis.- Animal Species as Models of Spontaneous and Induced Hyperlipidemias: A Critical Appraisal.- Rabbit Models Hypo- or Hyperresponsive to Changes in Diet.- Plasma Lipoproteins and Cholesterol Metabolism in a Strain of Hyperlipemic Rats.- Spontaneous Hypertriglyceridemia in a Non-Obese Rat Model: The IVA-SIV Rat.- Considerations for Controlled Clinical Testing of Safety and Efficacy of New Hypolipidemic Drugs.- Desirable Lipoprotein Parameters in Early Drug Trials.- Metabolic Studies with Lovastatin in Patients with Primary Hypercholesteremia.- Reduction of Plasma Lipids and Lipoproteins by Dietary Fish Oils in Patients with Hypertriglyceridemia.- Effects of Monounsaturated Fatty Acids Versus Complex Carbohydrates on Serum Lipoprotein Subfractions and Apolipoproteins in Healthy Men and Women.- Changes of Eicosanoid Formation in Relation to Dietary Lipids and in Hyperlipaemia.- Effects of Omega-3 Polyunsaturated Fatty Acids on Human Leukocyte Function and Biochemistry.- Dietary and Biochemical Studies with Textured Soy Proteins.- Detection of Reactive Free Radicals in Livers of Ethanol-Fed Rats: Potentiating Effect of High Fat Diets.- The Role of the Antioxidant Tocopherol in Lipid and Lipoprotein Metabolism.- Newer Aspects of Fats and Lipid Metabolism.- Can We Retard Atherogenesis by Modifying High-Density Lipoprotein Metabolism?.- Effects of Lipid-Lowering Drugs on High Density Lipoprotein Structure and Metabolism.- Enzyme-Inducers and High-Density Lipoproteins.- Gonadal Steroids and Hormone Antagonists.- The Effects of Adrenoceptor and Adrenergic Blocking Drugs on Plasma Lipoproteins.- The Influence of Terpenes and Analogues on Parameters of Atherosclerosis.- Initial Stages of Reverse Transport of Cholesterol.- Lipolytic Enzymes and HDL: Influence of Drugs and Hormones.- Human Apolipoprotein A-I and A-II Metabolism.- Roles of LCAT and Lipid Transfer Protein in HDL Metabolism.- The Profile of an HMG-CoA Reductase Inhibitor, CS-514(SQ 31,000).- Induction of Hepatic Low-Density Lipoprotein Receptors in Heterozygous WHHL Rabbits Treated with CS-514 Alone or CS-514 in Combination with Cholestyramine.- The Clinical Pharmacology of SQ 31,000 (CS 514) in Healthy Subjects.- Long-Term Effects of CS-514 on Serum Lipoprotein Lipid and Apolipoprotein Levels in Patients with Familial Hypercholesterolemia.- Intensive Drug Treatment for Familial Hypercholesterolemia.- Effect of CS-514 on Hypercholesterolemic Patients.- Hyperlipoproteinemia and Therapy: Results of a Multicenter Trial with Bezafibrate, a New Lipid-Lowering Drug.- Lipoprotein Changes Induced by Bezafibrate — 200 mg t.i.d. — and by Bezafibrate in a Slow-Release Preparation — 400 mg Once a Day — in Patients with Primary Hyperlipoproteinaemia.- Modifications of Apoprotein, Lipoprotein Parameters and HDL2 and HDL3 Subfractions During Treatment with Bezafibrate Retard.- Effect of Bezafibrate Retard on Plasma Lipoproteins in Hypertriglyceridemic Patients With and Without Diabetes Mellitus.- Long-Term Experience of a Single Daily Dose of Bezafibrate Retard 400 in Hyperlipoproteinaemia of Types IIa, IIb and IV.- Effects of Bezafibrate on Lipoprotein Metabolism in Cell Culture.- Efficacy and Tolerance of Fenofibrate: A Ten-Year Experience.- Mechanism of Action of Fenofibrate: New Data.- Species Differences in the Metabolic Disposition of Fenofibrate.- Pharmacokinetics of Lipanthyl in the Elderly.- Effect of Fenofibrate on Lipoprotein Particles Predictive of Coronary Atherosclerosis.- Tentative Biochemical Approach to Fenofibrate Efficacy in Tinnitus Aurium.- Clinical Effect of Lipanthyl on Tinnitus Aurium and Other Symptoms Related to Inner Ear Disorders.- Effect of Gemfibrozil Administration on Biliary Lipid Secretion: A Crossover Study with Clofibrate.- Plasma Lipids, Lipoproteins, and Apoproteins During Gemfibrozil Treatment in Primary Hyperlipidemias.- Effects of Gemfibrozil on Lipoproteins in Patients with Dyslipoproteinemia.- HDL Deficiency, Atherosclerosis, and Stimulation of HDL Synthesis: Role of Gemfibrozil.- Hemorheological Activity of Gemfibrozil in Primary Hyperlipidemias.- Evaluation of Hypolipidemic and Other Useful Pharmacological Properties of Various Nicotinic Acid Derivatives.- Pharmacokinetics and Metabolism of 2-Tert-Butyl-4-Cyclohexyl-Phenyl Nicotinate (L-44) in Rats.- Effects of Etofibrate on Risk Factors of Atherosclerosis.- Hyperaggregability of Platelets in Patients with Hyperlipoproteinemia Type IIb Under Treatment with Etofibrate Retard and Acetylsalicylic Acid.- Effect of Etofibrate on Platelet Function in Hyperlipidemic Patients.- Importance of Phospholipids in Cholesterol-Solubilizing Capacity of High-Density Lipoproteins.- Effects of Polyunsaturated Phospholipid on Cholesterol Efflux in Vitro and in Experimental Animals and Human Subjects.- Phospholipids in Human Atherosclerosis.- Effect of Polyunsaturated Phosphatidylcholine (PPC) on Plasma Lipoproteins in Patients with Type II Hyperlipoproteinemia.- Dietary Lecithin: Metabolism, Fate, and Effects on Metabolism of Lipids and Lipoproteins.- Effects of Pantethine on Lipid Metabolism in Isolated Rat Hepatocytes.- Effects of Pantethine on Experimental Atherosclerosis in Rabbits.- Modified LDL in Humans: Effect of Pantethine.- Changes in Platelet Membrane Lipid Composition Following Pantethine Administration.- Pantethine Treatment in Type III Hyperlipoproteinemia.